middle.news
How Clarity’s Cu-SAR-bisPSMA Is Changing Prostate Cancer Detection
9:35am on Tuesday 14th of October, 2025 AEDT
•
Healthcare
Read Story
How Clarity’s Cu-SAR-bisPSMA Is Changing Prostate Cancer Detection
9:35am on Tuesday 14th of October, 2025 AEDT
Key Points
Co-PSMA trial meets primary endpoint with superior lesion detection
Cu-SAR-bisPSMA outperforms Ga-PSMA-11 PET/CT in low PSA prostate cancer patients
Findings build on positive COBRA and PROPELLER trial results
Supports potential for earlier, more precise prostate cancer recurrence diagnosis
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Clarity Pharmaceuticals (ASX:CU6)
OPEN ARTICLE